.
.
Slavik T, Asselah F, Fakhruddin N, El Khodary A, Torjman F, Anis E, Quinn M, Khankan A, Kerr KM.
.
Clin Lung Cancer. 2014 Nov;15(6):398-404. doi: 10.1016/j.cllc.2014.06.005. Epub 2014 Jun 21.
Abstract
The identification of tumor biomarkers provides information on the prognosis and guides the implementation of appropriate treatment in patients with many different cancer types. In non-small cell lung cancer (NSCLC), targeted treatment plans based on biomarker identification have already been used in the clinic. However, such predictive molecular testing is not currently a universally used practice. This is the case, in particular, in developing countries where lung cancer is increasingly prevalent. In September 2012 and November 2013, a committee of 16 lung cancer experts from Africa and the Middle East met to discuss key issues related to diagnosis and biomarker testing in NSCLC and the implementation of personalized medicine in the region. The committee identified current challenges for effective diagnosis and predictive analysis in Africa and the Middle East. Moreover, strategies to encourage the implementation of biomarker testing were discussed. A practical approach for the effective diagnosis and predictive molecular testing of NSCLC in these regions was derived. We present the key issues and recommendations arising from the meetings. CI – Copyright © 2014 Elsevier Inc. All rights reserved.
Keywords: .
Link/DOI: 10.1016/j.cllc.2014.06.005